Introducing the first and
FDA-approved treatment
patients with polycythemia vera
an inadequate response to or are
In a phase 3 trial of Jakafi® (ruxolitinib) vs best available therapy:
21% of patients receiving Jakafi achieved the primary composite end point
of hematocrit (Hct) control and spleen volume reduction compared with <1%
of patients on best available therapy at week 32 (P < 0.0001)*
Indications and Usage
Jakafi is indicated for treatment of patients with
polycythemia vera who have had an inadequate
response to or are intolerant of hydroxyurea.
Important Safety Infor